四联疗法治疗幽门螺杆菌相关性胃溃疡临床疗效

Clinical Efficacy of Quadruple Therapy in the Treatment of Helicobacter Pylori-Associated Gastric Ulcers

目的探讨四联疗法治疗幽门螺杆菌(Hp)相关性胃溃疡的临床疗效。方法选取医院2022年3月至2023年1月收治的Hp相关性胃溃疡患者84例,按入院顺序分为对照组和观察组,各42例。两组患者均采用三联疗法(兰索拉唑肠溶片、阿莫西林胶囊、左氧氟沙星片口服),观察组患者在此基础上加用胶体果胶铋胶囊口服。均连续治疗14 d。结果观察组患者的总有效率为95.24%,显著高于对照组的76.19%(P<0.05)。治疗后,观察组患者的黏膜厚度、腺体密度及炎性细胞变化均显著优于对照组(P<0.05)。观察组患者的总不良反应发生率为7.14%,显著低于对照组的26.19%(P<0.05)。结论四联疗法治疗Hp相关性胃溃疡,可提高临床疗效,改善胃黏膜形态学。

Objective To investigate the clinical efficacy of quadruple therapy in the treatment of Helicobacter pylori(HP)-associated gastric ulcers.Methods A total of 84 patients with Hp-related gastric ulcers admitted to the hospital from March 2022 to January 2023 were selected and divided into the control group and the observation group by the order of admission,with 42 cases in each group.Both groups received triple therapy(oral administration of Lansoprazole Enteric-Coated Tablets,Amoxicillin Capsules,and Levofloxacin Tablets),while the observation group received oral administration of Colloidal Pectin Bismuth Capsules on this basis.All patients were treated continuously for 14 d.Results The total effective rate in the observation group was 95.24%,which was significantly higher than 76.19%in the control group(P<0.05).After treatment,the mucosal thickness,glandular density,and inflammatory cell changes in the observation group were significantly better than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group was 7.14%,which was significantly lower than 26.19%in the control group(P<0.05).Conclusion Quadruple therapy in the treatment of Hp-related gastric ulcers can improve clinical efficacy and gastric mucosal morphology.